Beyond Air 3Q 2026: Revenue $2.32M, EPS ($3.76) — 10-Q Summary
Beyond Air reported 3Q 2026 revenue of $2.32M, up 28% YoY, with a gross profit of $197K, reversing a prior-year loss. Net loss narrowed slightly. R&D expenses fell to $1.6M. LungFit GO received FDA Breakthrough Device Designation. The company expects to close the NeuroNOS divestiture in December 2026.
How this was made

The 30-second read
Why it matters
The earnings beat on revenue and loss narrowing may provide a short‑term catalyst for the stock, though the absolute figures remain small.
Market read
Micro‑cap earnings release with modest improvements; limited broader market impact.
What to watch
The FDA Breakthrough Device Designation for LungFit GO could drive future upside not reflected in the current numbers.
Background
Beyond Air, Inc. (NASDAQ: XAIR) filed its Form 10‑Q for Q3 2026, showing a 28% YoY revenue increase and a narrowed net loss.
Ticker impact
Beyond Air reported Q3 2026 revenue of $2.32M and a narrowed net loss, marking the first public disclosure of its quarterly results.
potential slight upside as the market prices in the loss narrowing
The company is a micro‑cap; the numbers are modest, but the improvement in gross profit and loss may attract short‑term buying.
Market effects
Limited impact on the broader med‑tech sector; signals incremental progress for lung‑fit devices.
Primarily U.S. micro‑cap investors; no broader regional effect.
Low global relevance.
Counterpoint
Investors may view the modest revenue and continued losses as a sign of ongoing cash‑burn, suggesting caution.
Key entities
- companyBeyond Air, Inc.
Medical device company focused on lung‑fit technologies.

